e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Molecular markers: diagnosis and management of malignant pleural effusions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic value of promoter hypermethylation of tumor suppressor genes in malignant pleural fluid
M. Botana-Rial, L. de Chiara, V. Leiro-Fernández, D. Valverde, C. Represas- Represas, A. I. González-Silva, A. Fernández-Villar (Vigo, Spain)
Source:
Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Session:
Molecular markers: diagnosis and management of malignant pleural effusions
Session type:
Poster Discussion
Number:
3544
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Botana-Rial, L. de Chiara, V. Leiro-Fernández, D. Valverde, C. Represas- Represas, A. I. González-Silva, A. Fernández-Villar (Vigo, Spain). Prognostic value of promoter hypermethylation of tumor suppressor genes in malignant pleural fluid. Eur Respir J 2011; 38: Suppl. 55, 3544
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Diagnostic value of detection of promoter hypermethylation of tumor suppressor genes in pleural fluid for diagnosis of malignant pleural effusion
Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach
Year: 2010
Alteration of p53 and FHIT genes in pleural effusion associated with malignancy
Source: Eur Respir J 2002; 20: Suppl. 38, 2s
Year: 2002
The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule
Source: Annual Congress 2009 - Pathogenesis of lung cancer
Year: 2009
Tumoural tissue specific promoter hypermethylation of distinct tumour suppressor genes in a case with nonsmall cell lung carcinoma: a case report
Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer
Year: 2009
Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathological characteristics of primary non small cell lung carcinoma
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012
Aberrant methylation of p16 tumour suppresor gene and DAP kinase in nonsmall cell lung carcinomas
Source: Eur Respir J 2001; 18: Suppl. 33, 233s
Year: 2001
Is caveolin-1 lost as a tumor suppressor gene in lung carcinoma?
Source: Annual Congress 2004 - Lung development and cancer
Year: 2004
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Suppression of HIF-1a dependent gene regulation by the tumour suppressor gene PTEN in pulmonary cells
Source: Eur Respir J 2001; 18: Suppl. 33, 17s
Year: 2001
Diagnostic and prognostic significance of survivin levels in malignant pleural effusion
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011
The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008
5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin
Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management
Year: 2018
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM)
Source: Eur Respir J 2004; 24: Suppl. 48, 81s
Year: 2004
Diagnostic utility of thyroid transcription factor (TTF1) expression in pleural effusions
Source: Annual Congress 2008 - Pleural effusion
Year: 2008
Different prevalence of positivity for human mammaglobin (hMAM) transcipts in the pleural fluid of patients with malignant
vs.
non malignant pleural disease
Source: Eur Respir J 2006; 28: Suppl. 50, 580s
Year: 2006
Malignant pleural effusion cells show aberrant glucose metabolism gene expression
Source: Eur Respir J 2011; 37: 1453-1465
Year: 2011
Mutations in the retinoblastoma-related gene RB2/p130 in lung tumours and suppression of tumour growth
in vivo
by retrovirus-mediated gene transfer
Source: Annual Congress 2002 - Thoracic oncology: biology
Year: 2002
Correlation of P53 and CerbB-2 expression in the diagnostic biopsies and the corresponding resected tumors in non small cell lung caner
Source: Eur Respir J 2004; 24: Suppl. 48, 43s
Year: 2004
Prognostic significance of MUC1 expression in resected lung adenocarcinoma
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept